VAM
ALXN

Verity Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Verity Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,282
Closed -$490K – 184
2020
Q3 		$490K Buy
4,282
+1,020
+31% +$110K 0.37% 69
2020
Q2 		$366K Sell
3,262
-284
-8% -$30.2K 0.34% 73
2020
Q1 		$318K Sell
3,546
-210
-6% -$20.6K 0.4% 82
2019
Q4 		$406K Buy
3,756
+24
+0.6% +$2.57K 0.4% 81
2019
Q3 		$366K Buy
3,732
+890
+31% +$100K 0.38% 84
2019
Q2 		$372K Buy
2,842
+112
+4% +$14.4K 0.42% 81
2019
Q1 		$369K Sell
2,730
-356
-12% -$44.3K 0.43% 70
2018
Q4 		$300K Buy
3,086
+131
+4% +$15.5K 0.4% 69
2018
Q3 		$411K Buy
2,955
+435
+17% +$54.6K 0.41% 59
2018
Q2 		$313K Buy
+2,520
New +$295K 0.28% 74
2018
Q1 		– Sell
-2,626
Closed -$313K – 150
2017
Q4 		$313K Buy
2,626
+454
+21% +$55.3K 0.24% 77
2017
Q3 		$260K Sell
2,172
-736
-25% -$100K 0.2% 92
2017
Q2 		$354K Buy
2,908
+482
+20% +$56.1K 0.27% 62
2017
Q1 		$294K Buy
+2,426
New +$313K 0.24% 76

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Verity Asset Management's ALXN Position: Q4 2020 in Review

Verity Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 4,282 shares — an estimated $490K sold.

Verity Asset Management first reported a position in ALXN in Q1 2017 and held it in 14 quarters. The position peaked at $490K in Q3 2020. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Verity Asset Management reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Verity Asset Management sold 4,282 Alexion Pharmaceuticals shares in Q4 2020, an estimated $490K.
  • Verity Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 14 quarters.
  • Verity Asset Management's Alexion Pharmaceuticals position peaked at $490K in Q3 2020.
  • 827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Verity Asset Management's 13F filing for Q4 2020, filed 5 Feb 2021.